teaser
The European Medicines Agency has released a guideline on how pharmaceutical companies should test biosimilar medicines containing interferon beta for public consultation.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
The guideline covers the non-clinical and clinical requirements for interferon beta-containing medicines that claim to be similar to another interferon beta already on the market.
Interferon beta-containing medicines are currently used to treat patients with multiple sclerosis.
The guideline was adopted by the Agency’s Committee for Medicinal Products for Human Use (CHMP) in December 2011. It is open for consultation until the end of May 2012.
